0001193125-26-091540
SEC filingStevanato Group S.p.A. reported strong FY 2025 results with revenue of $1.19B, up 7.4% YoY from $1.10B in 2024, driven by 11.2% growth in Biopharmaceutical and Diagnostic Solutions to $1.04B, offsetting a 13.0% decline in Engineering to $148.1M. High-value solutions contributed 46% of revenue, up 29.4% YoY. Gross profit rose 13.7% to $343.9M (29.0% margin vs. 27.4% prior year), reflecting favorable product mix and operational improvements. Operating profit increased 23.4% to $198.8M (16.8% margin), with net profit up 18.7% to $139.8M ($0.51 basic EPS). Cash from operations surged to $286.1M from $155.8M, supporting $272.9M capex mainly for EZ-fill expansions in U.S. and Italy. Balance sheet strengthened with total assets at $2.54B and equity at $1.49B. Despite tariff impacts and ramp-up inefficiencies, the company advanced capacity expansions and high-value solutions, positioning for biologics growth amid stabilizing vial demand.
Stevanato Group delivered robust FY 2025 performance with revenue reaching $1.19B, a 7.4% YoY increase from $1.10B in 2024. Growth was propelled by Biopharmaceutical and Diagnostic Solutions segment, up 11.2% to $1.04B (88% of total), driven by 29.4% surge in high-value solutions to $546.4M (46% of revenue). Engineering segment declined 13.0% to $148.1M amid project mix challenges. Gross profit climbed 13.7% to $343.9M (29.0% margin vs. 27.4%), aided by favorable mix and efficiency gains. Operating profit rose 23.4% to $198.8M (16.8% margin), net profit increased 18.7% to $139.8M ($0.51 EPS). Operating cash flow doubled to $286.1M, funding $294.9M capex for capacity expansions.
Biopharmaceutical and Diagnostic Solutions generated $1.04B (+11.2% YoY), with high-value solutions at $546.4M (+29.4%), reflecting demand for EZ-fill vials/cartridges and high-performance syringes. Other solutions dipped 3.8% to $491.8M due to vial stabilization post-destocking. Engineering revenue fell 13.0% to $148.1M from lower glass converting and inspection systems, offset by after-sales growth. Geographically, North America contributed 30.5% ($362.1M, +17.2% YoY), EMEA 58.2% ($690.3M, +3.4%). High-value solutions now 46% of total revenue vs. 38.3% prior year, signaling successful premium shift.
Gross margin expanded to 29.0% from 27.4%, driven by high-value mix (31.5% BDS margin vs. 28.7%), Fishers/Latina ramp-up efficiencies, and vial profitability. BDS operating margin improved to 21.2% (17.7% prior), while Engineering dropped to 3.3% (9.3%) on legacy project costs. R&D expenses fell 19.7% to $25.4M (2.1% revenue), reflecting focused portfolio. G&A rose 6.3% to $99.7M (8.4% revenue) on hiring/IT costs. Net finance expense widened to $9.7M from currency impacts. Effective tax rate 26.1% vs. 26.5%.
Operating cash flow surged 83.6% to $286.1M, fueled by $189.1M PBT, $88.6M depreciation, and $91.2M payables increase, offset by $41.5M inventory build. Investing outflows $272.9M (capex $294.9M for EZ-fill expansions). Financing net inflow $22.1M from $150M borrowings offset by repayments/dividends. Cash rose to $130.6M. Total assets $2.54B (+9.2%), equity $1.49B (+5.8%). Net debt stable at $337.7M. Current ratio 1.76x.
Management highlights ongoing EZ-fill ramps in U.S./Italy through 2026, biologics/vaccine demand stabilization, and high-value solutions growth. Engineering optimization targets profitable expansion. BARDA funding supports U.S. capacity. Risks include tariffs, forex volatility, and execution delays. Committed orders ~€94M net of BARDA.